Cargando…

Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-Antagonist

PURPOSE: To assess the neuroprotective effects of flibanserin (formerly BIMT-17), a dual 5-HT(1A) agonist and 5-HT(2A) antagonist, in a light-induced retinopathy model. METHODS: Albino BALB/c mice were injected intraperitoneally with either vehicle or increasing doses of flibanserin ranging from 0.7...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coyner, Aaron S., Ryals, Renee C., Ku, Cristy A., Fischer, Cody M., Patel, Rachel C., Datta, Shreya, Yang, Paul, Wen, Yuquan, Hen, René, Pennesi, Mark E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957778/ https://www.ncbi.nlm.nih.gov/pubmed/27447833 http://dx.doi.org/10.1371/journal.pone.0159776

Ejemplares similares

The Role of ERK1/2 Activation in Sarpogrelate-Mediated Neuroprotection
por: Ku, Cristy A., et al.
Publicado: (2018)

Flibanserin Approval: Facts or Feelings?
por: Simon, James A., et al.
Publicado: (2016)

Long-term Characterization of Retinal Degeneration in Royal College of Surgeons Rats Using Spectral-Domain Optical Coherence Tomography
por: Ryals, Renee C., et al.
Publicado: (2017)

Flibanserin: Approval of a controversial drug for a controversial disorder
por: Sathyanarayana Rao, T. S., et al.
Publicado: (2015)

Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery
por: Colón, Jennifer M., et al.
Publicado: (2016)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Flibanserin for Treating Hypoactive Sexual Desire Disorder
por: Sang, Jae Hong, et al.
Publicado: (2016)

Female sexual dysfunction: a focus on flibanserin
por: Lodise, Nicole M
Publicado: (2017)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

The Optimization and Evaluation of Flibanserin Fast-Dissolving Oral Films
por: Alghaith, Adel F., et al.
Publicado: (2022)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Editorial note: repurposing FDA approved drugs as FXR agonists: a structure based in silico pharmacological study
Publicado: (2022)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Flibanserin: A controversial drug for female hypoactive sexual desire disorder
por: Baid, Rashmi, et al.
Publicado: (2018)

Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route
por: Ahmed, Osama A. A., et al.
Publicado: (2020)

Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
por: Illenberger, Jessica M., et al.
Publicado: (2023)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_icf5j8cl1tgig7mfkfpf6l390b